110 related articles for article (PubMed ID: 2714846)
1. Influence of factor D concentrations on fluid phase C3 activation, lysis of rabbit erythrocytes and solubilization of immune complexes.
Sturfelt G; Sjöholm AG; Truedsson L
Immunol Lett; 1989 Feb; 20(3):231-6. PubMed ID: 2714846
[TBL] [Abstract][Full Text] [Related]
2. Decreased capacity to solubilize immune complexes in sera from patients with systemic lupus erythematosus.
Aguado MT; Perrin LH; Miescher PA; Lambert PH
Arthritis Rheum; 1981 Oct; 24(10):1225-9. PubMed ID: 7306225
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of immune complex solubilization: complement function in relation to disease activity in SLE.
Sturfelt G; Nived O; Sjöholm AG
Clin Exp Rheumatol; 1992; 10(3):241-7. PubMed ID: 1582069
[TBL] [Abstract][Full Text] [Related]
4. Complement breakdown products in plasma from patients with systemic lupus erythematosus and patients with membranoproliferative or other glomerulonephritis.
Perrin LH; Lambert PH; Miescher PA
J Clin Invest; 1975 Jul; 56(1):165-76. PubMed ID: 1141431
[TBL] [Abstract][Full Text] [Related]
5. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
[TBL] [Abstract][Full Text] [Related]
6. Activation of the guinea pig alternative complement pathway by mouse IgA immune complexes.
Pfaffenbach G; Lamm ME; Gigli I
J Exp Med; 1982 Jan; 155(1):231-47. PubMed ID: 7054357
[TBL] [Abstract][Full Text] [Related]
7. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway.
Boackle RJ; Caughman GB; Vesely J; Medgyesi G; Fudenberg HH
Mol Immunol; 1983 Nov; 20(11):1157-64. PubMed ID: 6228720
[TBL] [Abstract][Full Text] [Related]
9. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
[TBL] [Abstract][Full Text] [Related]
10. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
11. Binding to erythrocyte complement receptor type 1 of BSA/anti-BSA complexes opsonized by C4A3 or C4B1 in the presence of serum.
Klint C; Truedsson L; Sturfelt G
Scand J Immunol; 1995 Oct; 42(4):425-32. PubMed ID: 7569775
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of free sialic acid on complement activation and its significance in hypocomplementemic glomerulonephritis.
Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
J Clin Lab Anal; 1999; 13(4):173-9. PubMed ID: 10414597
[TBL] [Abstract][Full Text] [Related]
13. Complement activation during an active cytomegalovirus infection after renal transplantation: due to circulating immune complexes or alternative pathway activation?
van Son WJ; van der Bij W; Tegzess AM; Anema J; van der Giessen M; van der Hem GK; Marrink J; The TH
Clin Immunol Immunopathol; 1989 Jan; 50(1 Pt 1):109-21. PubMed ID: 2535976
[TBL] [Abstract][Full Text] [Related]
14. The attachment of serum- and plasma-derived C3 to solid-phase immune aggregates and its relation to complement-mediated solubilization of immune complexes.
Baatrup G; Svehag SE; Jensenius JC
Scand J Immunol; 1986 Apr; 23(4):397-406. PubMed ID: 3486458
[TBL] [Abstract][Full Text] [Related]
15. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
Takata Y; Tamura N; Fujita T
J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
[TBL] [Abstract][Full Text] [Related]
16. Natural hemolytic and bactericidal activities of sea bream Sparus aurata serum are effected by the alternative complement pathway.
Sunyer JO; Tort L
Vet Immunol Immunopathol; 1995 Apr; 45(3-4):333-45. PubMed ID: 7676614
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
[TBL] [Abstract][Full Text] [Related]
19. [Concentration-functional interrelationships in the human alternative complement activation pathway].
Galebskaia LV; Shcherbak IG; Bel'tiukov PP; Riumina EV; Solovtsova IL
Biokhimiia; 1993 Nov; 58(11):1796-800. PubMed ID: 8268316
[TBL] [Abstract][Full Text] [Related]
20. Non-covalently bound C3 enhances lysis of rabbit erythrocytes through the alternative pathway.
Hidvégi T; Füst G; Rajnavölgyi E; Kulics J; Gergely J
Immunology; 1985 Dec; 56(4):735-41. PubMed ID: 3935572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
